HK1207368A1 - 用於治療尤文肉瘤家族腫瘤的方法和組合物 - Google Patents
用於治療尤文肉瘤家族腫瘤的方法和組合物Info
- Publication number
- HK1207368A1 HK1207368A1 HK15107941.8A HK15107941A HK1207368A1 HK 1207368 A1 HK1207368 A1 HK 1207368A1 HK 15107941 A HK15107941 A HK 15107941A HK 1207368 A1 HK1207368 A1 HK 1207368A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tumors
- compositions
- treating
- methods
- sarcoma family
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623349P | 2012-04-12 | 2012-04-12 | |
| PCT/US2013/036234 WO2013155341A1 (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207368A1 true HK1207368A1 (zh) | 2016-01-29 |
Family
ID=49328171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107941.8A HK1207368A1 (zh) | 2012-04-12 | 2015-08-17 | 用於治療尤文肉瘤家族腫瘤的方法和組合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9290449B2 (zh) |
| EP (1) | EP2836481B1 (zh) |
| JP (2) | JP6130491B2 (zh) |
| KR (1) | KR102145835B1 (zh) |
| CN (2) | CN107011242B (zh) |
| AU (2) | AU2013245812B2 (zh) |
| CA (1) | CA2869513C (zh) |
| HK (1) | HK1207368A1 (zh) |
| IL (1) | IL234993B (zh) |
| IN (1) | IN2014DN09228A (zh) |
| MX (1) | MX2014011583A (zh) |
| NZ (2) | NZ700612A (zh) |
| WO (1) | WO2013155341A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| EP2836481B1 (en) | 2012-04-12 | 2018-12-26 | Georgetown University | Compounds and compositions for treating ewings sarcoma family of tumors |
| US9511050B2 (en) | 2013-10-24 | 2016-12-06 | Georgetown University | Methods and compositions for treating cancer |
| CA2961781C (en) * | 2014-10-09 | 2023-10-03 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
| US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| CA2977397A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| ES2823190T3 (es) * | 2016-03-31 | 2021-05-06 | Oncternal Therapeutics Inc | Análogos de indolina y usos de los mismos |
| KR102282794B1 (ko) | 2016-07-29 | 2021-07-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌리논 화합물의 용도 |
| CA3048065A1 (en) | 2016-12-21 | 2018-06-28 | Susan L. Mooberry | Altertoxin ii as a selective inhibitor of ewing family of tumor cells |
| CN108186630B (zh) * | 2017-12-18 | 2020-07-31 | 温州医科大学 | 靛红类似物在制备抗肿瘤药物中的应用 |
| CN110870917B (zh) * | 2018-09-03 | 2022-03-15 | 上海市第一人民医院 | Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用 |
| US12076310B2 (en) * | 2021-06-09 | 2024-09-03 | University Of Rochester | Compounds and methods for the treatment of acute myelogenous leukemia |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
| WO2023178040A2 (en) * | 2022-03-13 | 2023-09-21 | University Of Virginia Patent Foundation | Inhibitors of ews-fli1 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| JP2002531498A (ja) | 1998-12-04 | 2002-09-24 | ニューロサーチ、アクティーゼルスカブ | イオンチャネル活性剤としてのイサチン誘導体の使用方法 |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| JP4584987B2 (ja) | 2004-04-30 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | Ｃ５修飾ピリミジンを含むオリゴヌクレオチド |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| WO2008046083A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| EP2124910A4 (en) | 2006-12-29 | 2012-02-15 | Univ Georgetown | ANTITUMOR THERAPY BY TARGETING EWS-FLI1 |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| JP5400032B2 (ja) * | 2007-04-20 | 2014-01-29 | ザ リサーチ ファウンデーション オブ ザ ステイト ユニヴァーシティ オブ ニューヨーク | ベンズイミダゾール及びその医薬組成物 |
| US8377992B2 (en) * | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| WO2010083505A1 (en) | 2009-01-19 | 2010-07-22 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| EP2836481B1 (en) * | 2012-04-12 | 2018-12-26 | Georgetown University | Compounds and compositions for treating ewings sarcoma family of tumors |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| US9511050B2 (en) | 2013-10-24 | 2016-12-06 | Georgetown University | Methods and compositions for treating cancer |
| CA2961781C (en) | 2014-10-09 | 2023-10-03 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
-
2013
- 2013-04-11 EP EP13776244.9A patent/EP2836481B1/en active Active
- 2013-04-11 WO PCT/US2013/036234 patent/WO2013155341A1/en active Application Filing
- 2013-04-11 CN CN201611030609.9A patent/CN107011242B/zh active Active
- 2013-04-11 KR KR1020147031650A patent/KR102145835B1/ko active IP Right Grant
- 2013-04-11 US US14/388,671 patent/US9290449B2/en active Active
- 2013-04-11 NZ NZ700612A patent/NZ700612A/en unknown
- 2013-04-11 IN IN9228DEN2014 patent/IN2014DN09228A/en unknown
- 2013-04-11 CA CA2869513A patent/CA2869513C/en active Active
- 2013-04-11 AU AU2013245812A patent/AU2013245812B2/en active Active
- 2013-04-11 JP JP2015505921A patent/JP6130491B2/ja active Active
- 2013-04-11 NZ NZ723971A patent/NZ723971A/en unknown
- 2013-04-11 CN CN201380030414.2A patent/CN104395288B/zh active Active
- 2013-04-11 MX MX2014011583A patent/MX2014011583A/es active IP Right Grant
-
2014
- 2014-10-05 IL IL234993A patent/IL234993B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107941.8A patent/HK1207368A1/zh unknown
-
2016
- 2016-02-10 US US15/040,840 patent/US9714222B2/en active Active
-
2017
- 2017-03-06 AU AU2017201507A patent/AU2017201507B2/en active Active
- 2017-04-13 JP JP2017080017A patent/JP6345301B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6345301B2 (ja) | 2018-06-20 |
| US20160159741A1 (en) | 2016-06-09 |
| JP6130491B2 (ja) | 2017-05-17 |
| IN2014DN09228A (zh) | 2015-07-10 |
| KR20150007311A (ko) | 2015-01-20 |
| CN107011242B (zh) | 2020-08-07 |
| NZ723971A (en) | 2018-01-26 |
| CA2869513C (en) | 2020-07-07 |
| WO2013155341A1 (en) | 2013-10-17 |
| AU2013245812B2 (en) | 2017-04-06 |
| JP2017141290A (ja) | 2017-08-17 |
| AU2013245812A1 (en) | 2014-11-13 |
| CN104395288B (zh) | 2016-12-14 |
| AU2017201507B2 (en) | 2018-10-04 |
| AU2017201507A1 (en) | 2017-03-23 |
| EP2836481B1 (en) | 2018-12-26 |
| MX2014011583A (es) | 2016-02-09 |
| CN104395288A (zh) | 2015-03-04 |
| CN107011242A (zh) | 2017-08-04 |
| NZ700612A (en) | 2016-09-30 |
| US20150051260A1 (en) | 2015-02-19 |
| EP2836481A1 (en) | 2015-02-18 |
| JP2015512943A (ja) | 2015-04-30 |
| EP2836481A4 (en) | 2015-11-18 |
| US9290449B2 (en) | 2016-03-22 |
| US9714222B2 (en) | 2017-07-25 |
| AU2013245812A2 (en) | 2014-11-20 |
| IL234993B (en) | 2019-02-28 |
| KR102145835B1 (ko) | 2020-08-20 |
| CA2869513A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288181A (en) | Cancer treatment methods | |
| HK1207368A1 (zh) | 用於治療尤文肉瘤家族腫瘤的方法和組合物 | |
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| HK1209798A1 (zh) | 用於治療癌症的組合物和方法 | |
| EP2836482A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
| HK1214521A1 (zh) | 用於治療蛋白質病的組合物和方法 | |
| EP2890720A4 (en) | COMPOSITIONS AND METHODS OF TREATING CANCER | |
| EP2688594A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| EP2828241A4 (en) | COMPOSITIONS AND METHOD FOR INHIBITING CATHEPSINES | |
| IL239374B (en) | Preparations and methods for treating brain tumors | |
| HK1216854A1 (zh) | 用於治療癌症的組合物和方法 | |
| EP2863939A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP2928456A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP2841102A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP2822593A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER |